Evidence map›Paper›PMID 38585952›Full record

ArticlebioRxiv : the preprint server for biology2024

Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer.

Sanghoon Lee, Youngbin Cho, Yiting Li, Ruxuan Li, Daniel Brown, Priscilla McAuliffe, Adrian V Lee, Steffi Oesterreich, Ioannis K Zervantonakis, Hatice Ulku Osmanbeyoglu

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sanghoon LeeDepartment of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, 15206, U.S.A.
Youngbin ChoUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, 15213 U.S.A.
Yiting LiWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, PA, 15213, U.S.A.
Ruxuan LiUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, 15213 U.S.A.
Daniel BrownWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, PA, 15213, U.S.A.
Priscilla McAuliffeWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, PA, 15213, U.S.A.
Adrian V LeeWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, PA, 15213, U.S.A.ORCID 0000-0001-9917-514X
Steffi OesterreichWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, PA, 15213, U.S.A.
Ioannis K ZervantonakisUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, 15213 U.S.A.ORCID 0000-0003-2386-9553
Hatice Ulku OsmanbeyogluDepartment of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, 15206, U.S.A.ORCID 0000-0002-3175-1777
University of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Developing and credentialing murine models of ILCR01CA252378 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Adrian V Lee, Steffi Oesterreich · 2021 to 2026
$3.0M
Computational methods for delineating cell context-specific regulatory programsR35GM146989 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Hatice Ulku Osmanbeyoglu · 2022 to 2026
$1.9M
Algorithms to link signaling pathways with transcriptional programs for precision medicineR00CA207871 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OSMANBEYOGLU, HATICE ULKU · 2019 to 2022
$738k
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
NCI NIH HHS P30 CA047904NCI NIH HHS R00 CA207871NCI NIH HHS R01 CA252378NIGMS NIH HHS R35 GM146989NIH HHS S10 OD028483
6 · The paper itself

Abstract

Macrophages are pivotal in driving breast tumor development, progression, and resistance to treatment, particularly in estrogen receptor-positive (ER+) tumors, where they infiltrate the tumor microenvironment (TME) influenced by cancer cell-secreted factors. By analyzing single-cell RNA-sequencing data from 25 ER+ tumors, we elucidated interactions between cancer cells and macrophages, correlating macrophage density with epithelial cancer cell density. We identified that S100A11, a previously unexplored factor in macrophage-cancer crosstalk, predicts high macrophage density and poor outcomes in ER+ tumors. We found that recombinant S100A11 enhances macrophage infiltration and migration in a dose-dependent manner. Additionally, in 3D models, we showed that S100A11 expression levels in ER+ cancer cells predict macrophage infiltration patterns. Neutralizing S100A11 decreased macrophage recruitment, both in cancer cell lines and in a clinically relevant patient-derived organoid model, underscoring its role as a paracrine regulator of cancer-macrophage interactions in the protumorigenic TME. This study offers novel insights into the interplay between macrophages and cancer cells in ER+ breast tumors, highlighting S100A11 as a potential therapeutic target to modulate the macrophage-rich tumor microenvironment.

Identifiers

PMID38585952
PMCPMC10996512
OpenAlexW4393200872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.